| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Peptides | Ophthalmologic System | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Peptides | Ophthalmologic System | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Peptides | Ophthalmologic System |
Recent Updates
Recently added Catalysts
OKYO Pharma Limited$1.69
-0.08 (-4.76%)
D 24Pipeline Score Richly Valued Biotech · Clinical
Market Cap
83.73 M
EPS
-0.13
P/E Ratio
-
Value Trade
53.24 K
3.16 %
Week
3.16 %
1 Month
-10.44 %
3 Month
-14.21 %
6 Month
-63.78 %
5 Year
-63.78 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
78.32 K
52 Week Range
1.44 - 3.35
% held by Insiders
32.56 %
% held by Institutions
20.33 %
Enterprise Value
79.70 M
Total Shares
40.55 M
Short %
0.14 %
Float Shares
23.52 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for OKYO Pharma Limited
241Total events
4Upcoming
47Tier-1 (high impact)
2020 – 2026Coverage
Upcoming catalysts 4
Event history 237
Jul 9, 2026
◆Oral PresentationPresentation
Participation in Piper Sandler 2026 Virtual Ophthalmology Symposium
Jul 8, 2026
▲Type D MeetingurcosimodFDA Meeting
Positive FDA Type D meeting feedback validating regulatory and clinical path for urcosimod
neuropathic corneal painsource ↗
Jul 7, 2026
▲Trial CompletionurcosimodTrial
Completed phase 2 trial of urcosimod in NCP
neuropathic corneal pain (NCP)source ↗
Q3 2026
◆Trial InitiationurcosimodTrial
Initiation of global Phase 3 pivotal trial NEPTUNE for urcosimod
neuropathic corneal painsource ↗
Jun 2026
◆Trial InitiationurcosimodTrial
Initiate ~150 subject Phase 2b/3 multiple-dose study of urcosimod to treat NCP
neuropathic corneal painsource ↗
May 5, 2026
◆Poster PresentationurcosimodPresentation
Poster presentation at ARVO: First-in-Human Study of Urcosimod Shows Clinically Meaningful Pain Reduction and Quality-of-Life Improvement in NCP Patients
Neuropathic Corneal Pain (NCP)source ↗
May 3, 2026
◆Poster PresentationurcosimodPresentation
Abstract accepted for presentation at ARVO 2026 Annual Meeting
neuropathic corneal pain (NCP)source ↗
May 1, 2026
◆Oral PresentationPresentation
CEO presentation at Eyecelerator: Addressing Unmet Needs in Corneal and Anterior Segment Diseases
Corneal and Anterior Segment Diseasessource ↗
Apr 11, 2026
◆Oral PresentationurcosimodPresentation
Abstract accepted for presentation at ASCRS 2026 Annual Meeting
neuropathic corneal painsource ↗
Mar 19, 2026
▲Topline ReadouturcosimodClinical Data
Positive Phase 2a data for urcosimod in NCP pain reduction
neuropathic corneal painsource ↗
Mar 18, 2026
▲Full ResultsurcosimodClinical Data
New Phase 2 data demonstrating meaningful improvements in patient-reported quality of life outcomes with urcosimod in neuropathic corneal pain
neuropathic corneal painsource ↗
Drug Pipeline Intelligence
D24
Pipeline Score $1M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 23%
Micro Cap (rank 702 of 911)
Percentile RankOKYO Pharma Limited faces pipeline headwinds (24/100), with $66M risk-adjusted pipeline value, led by OK-101 in Dry Eye Disease (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OK-101 Small molecule | Dry Eye Disease | Phase 2 | NCT05759208 | 15% | $66M | COMPLETED | 240 | - | - | Dec 15, 2023 | - | Feb 9, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Urcosimod Fast Track | neuropathic corneal pain | Phase 2 | 2026-04-29 | positive data on NCP pain reduction in a randomized, placebo-controlled, double-masked Phase 2 trial involving 18 neuropathic corneal pain patients. Read More | OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May Read More | |
Urcosimod Fast Track | neuropathic corneal pain | Phase 2 | 2026-04-29 | positive data on NCP pain reduction in a randomized, placebo-controlled, double-masked Phase 2 trial involving 18 neuropathic corneal pain patients. Read More | OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May Read More | |
Urcosimod Fast Track | neuropathic corneal pain | Phase 2 | 2026-04-29 | positive data on NCP pain reduction in a randomized, placebo-controlled, double-masked Phase 2 trial involving 18 neuropathic corneal pain patients. Read More | OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in OKYO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
OKYO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
OKYO▼ -5.1%on this news
OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain
OKYO Pharma has received positive feedback from the FDA regarding its Type D meeting, which supports the advancement of urcosimod into a global Phase 3 pivotal trial for neuropathic corneal pain. The trial, named NEPTUNE, will enroll approximately 111 subjects and aims to address the unmet medical need in this area. The FDA's feedback also provides clarity on the regulatory strategy, potentially allowing for a streamlined development pathway.
Read more →OKYO▲ +8.7%on this newsshared move
OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium
OKYO Pharma Limited will participate in the Piper Sandler Virtual Ophthalmology Symposium on July 9, 2026. The event will feature CEO Robert J. Dempsey and CMO Flavio Mantelli. OKYO is focused on developing therapies for neuropathic corneal pain and has recently completed a Phase 2 trial for its drug urcosimod.
Read more →OKYOOKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD
OKYO Pharma Limited has appointed Dr. Marta Sacchetti to its Scientific Advisory Board, enhancing its expertise in ocular inflammatory diseases. Dr. Sacchetti's extensive background in clinical and translational research will support OKYO's development strategy for neuropathic corneal pain treatments. The company recently reported positive results from its Phase 2 trials for its investigational therapy, Urcosimod.
Read more →OKYOOKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May
OKYO Pharma Limited announced that CEO Robert J. Dempsey will present at the Eyecelerator conference, while CSO Raj Patil will present findings on Urcosimod at the ARVO Annual Meeting. Urcosimod, the first investigational therapy for neuropathic corneal pain, has shown significant pain reduction in clinical trials. The company aims to enhance its presence in the ophthalmic field through these presentations.
Read more →OKYOOKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting
OKYO Pharma will hold a Scientific Advisory Board meeting during the ASCRS Annual Meeting to discuss the clinical data for urcosimod, its lead candidate for treating neuropathic corneal pain. Dr. Pedram Hamrah will present findings from a Phase 2 study on urcosimod's efficacy and safety. This dual presence at ASCRS marks a significant milestone for the company as it prepares for further clinical trials.
Read more →OKYOOKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting London and New York, NY
OKYO Pharma Limited announced it will conduct a Scientific Advisory Board meeting during the ASCRS Annual Meeting, featuring the presentation of data for its investigational therapy, urcosimod, aimed at treating neuropathic corneal pain. Dr. Pedram Hamrah will present findings from a Phase 2 study demonstrating the therapy's efficacy and safety. This conference is notable for its high-profile gathering of ophthalmology experts, and OKYO aims to refine its clinical strategies with insights from key opinion leaders. The company plans to initiate a Phase 2b/3 clinical trial in the near future, building on promising results from previous studies.
Read more →OKYOOKYO Pharma Announces Chief Development Officer and Director Acquires Shares
OKYO Pharma Limited announced that Chief Development Officer Gary Jacob acquired 30,980 shares, increasing his total to 108,920. The company is developing Urcosimod, which has shown promise in reducing neuropathic corneal pain (NCP) in recent trials. Following positive results from a Phase 2a trial, OKYO plans to initiate a Phase 2b/3 study this year.
Read more →OKYOOKYO Pharma Announces Director Acquires Shares
OKYO Pharma Limited announced that Non-Executive Director John Brancaccio has acquired an additional 5,000 shares in the company, raising his total holdings to 31,201 shares. The biopharmaceutical firm is advancing its investigational therapy, urcosimod, which has shown promise in reducing pain in neuropathic corneal pain patients in recent clinical trials. The company has plans to begin a larger Phase 2b/3 trial later this year, reflecting its ongoing commitment to developing treatments for inflammatory eye diseases.
Read more →OKYOOKYO Pharma Announces Chairman and Founder Acquires Shares London and New York, NY
OKYO Pharma Limited announced that Gabriele Cerrone, the Executive Chairman, has acquired an additional 10,119 shares, bringing his total to over 10.5 million shares. The company has recently reported positive outcomes from its Phase 2a trial of urcosimod in the reduction of neuropathic corneal pain. With ongoing developments, OKYO plans to initiate a Phase 2b/3 multiple-dose study of urcosimod in the near future. This acquisition by Cerrone may reflect his confidence in the company's potential and the successful trials conducted to date.
Read more →OKYOOKYO Pharma Announces Director Acquires Shares London and New York, NY
OKYO Pharma Limited has announced that Non-Executive Director John Brancaccio acquired 5,000 shares at $1.61, increasing his total holding to 31,201 shares. The company is focused on developing therapies for neuropathic corneal pain and inflammatory eye diseases. Recently, OKYO reported positive results from a Phase 2a trial on its investigational drug urcosimod, showing pain reduction in neuropathic corneal pain subjects. The company is planning to initiate a Phase 2b/3 study with approximately 150 subjects in the near future.
Read more →OKYOOKYO Pharma Announces Chief Development Officer and Director Acquires Shares London and New York, NY
OKYO Pharma Limited has announced that Gary Jacob, the Chief Development Officer and Director, has purchased nearly 31,000 ordinary shares of the company, raising his total holdings. This action comes alongside reports of positive outcomes from a randomized Phase 2a trial focusing on the company's investigational drug, urcosimod, for treating neuropathic corneal pain (NCP). Following the success of this trial, OKYO plans to start a larger Phase 2b/3 study within the next few months to further assess the efficacy of urcosimod.
Read more →OKYOOKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain London and New York, NY
OKYO Pharma has announced new positive findings from its Phase 2 trial of urcosimod for treating neuropathic corneal pain (NCP). The results highlight significant improvements in patient-reported quality of life metrics alongside pain reduction. The data will be presented at the ARVO 2026 Annual Meeting, emphasizing the potential holistic benefits of urcosimod beyond mere pain alleviation. This study represents a critical step towards addressing the unmet medical need in treating chronic ocular pain conditions, as there are currently no FDA-approved therapies for NCP.
Read more →OKYOOKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress
OKYO Pharma announced that its abstract on urcosimod has been accepted for presentation at the ARVO 2026 Annual Meeting. The presentation will detail positive results from a Phase 2a clinical trial, demonstrating significant pain reduction and quality-of-life improvements in patients with neuropathic corneal pain. The company plans to advance urcosimod into a larger Phase 2b/3 trial.
Read more →OKYOOKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress London and New York, NY
OKYO Pharma announced that its abstract has been selected for presentation at the ARVO 2026 Annual Meeting in Denver, Colorado. The presentation will detail results from a Phase 2a clinical trial of urcosimod, a novel treatment for neuropathic corneal pain (NCP), which showed significant pain reduction and improvement in quality of life for patients. Urcosimod has received FDA Fast Track designation and plans are underway for a larger Phase 2b/3 trial involving approximately 150 patients to further evaluate its efficacy and safety. The data emphasizes the unmet need in treating NCP, as no FDA-approved treatments currently exist.
Read more →OKYO▼ -19.4%on this news
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
OKYO Pharma Limited has announced the pricing of a public offering of 10,815,000 ordinary shares at $1.85 per share, aiming to raise approximately $20 million. The offering includes an option for underwriters to purchase additional shares, potentially increasing total proceeds to $23 million. The funds will primarily support clinical development and general corporate purposes. The offering is expected to close around February 17, 2026.
Read more →OKYO▼ -19.4%on this newsshared move
OKYO Pharma Announces Public Offering of Ordinary Shares
OKYO Pharma Limited has announced its intention to conduct a public offering of ordinary shares, which will be sold entirely by the company. The proceeds from this offering are primarily aimed at supporting clinical development and general corporate purposes. The offering's completion is contingent upon market conditions, and the company has granted the underwriter a 30-day option for additional shares.
Read more →OKYO▲ +11.3%on this newsshared move
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares London and New York, NY
OKYO Pharma Limited announced the pricing of a $20 million public offering, with 10,815,000 ordinary shares priced at $1.85 each. The underwriter has a 30-day option to purchase additional shares, potentially increasing the total proceeds to $23 million. Proceeds from the offering will be utilized for clinical development, corporate purposes, and working capital. The offering is set to close around February 17, 2026, pending customary conditions. This initiative follows the success of a Phase 2 trial for its drug urcosimod, aimed at treating neuropathic corneal pain.
Read more →OKYO▲ +11.3%on this newsshared move
OKYO Pharma Announces Public Offering of Ordinary Shares London and New York, NY
OKYO Pharma Limited announced its intention to conduct a public offering of ordinary shares to support its clinical development of treatments for neuropathic corneal pain and inflammatory eye diseases. The company plans to use the proceeds primarily for ongoing product development and general corporate purposes. Additionally, OKYO has recently achieved a successful Phase 2 trial results for its drug urcosimod and is set to initiate further studies. However, the offering is subject to market conditions, which could introduce uncertainties regarding its completion and terms.
Read more →OKYOOKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners
OKYO Pharma has transitioned its At-The-Market equity offering facility to Leerink Partners, replacing B. Riley Securities. This strategic move aims to enhance financial flexibility and maintain access to capital markets for ongoing clinical development. The company plans to initiate a Phase 2b/3 study of its lead candidate, urcosimod, for neuropathic corneal pain.
Read more →OKYO▲ +5%on this newsshared move
OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer
OKYO Pharma has appointed Dr. Flavio Mantelli as Chief Medical Officer, enhancing its leadership team. Dr. Mantelli brings extensive experience in ocular drug development, particularly with the successful launch of Oxervate. He will oversee the clinical development strategy for urcosimod, which is set to enter Phase 2b/3 trials for neuropathic corneal pain, a condition lacking FDA-approved therapies.
Read more →OKYOOKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting
OKYO Pharma announced that its abstract on urcosimod has been accepted for presentation at the 2026 ASCRS Annual Meeting. The study focuses on the efficacy and safety of urcosimod in treating neuropathic corneal pain. CEO Robert Dempsey expressed excitement about sharing positive Phase 2 data with leading ophthalmologists, as the company plans to advance to a larger Phase 2b/3 trial.
Read more →OKYOOKYO Pharma Interim Results for the Six Months Ended 30 September 2025 London and New York, NY
OKYO Pharma Limited reported its interim results for the six months ending September 30, 2025, highlighting significant milestones for its drug urcosimod for neuropathic corneal pain (NCP). The company achieved FDA Fast Track Designation and reported positive results from its Phase 2 trial. Despite a total comprehensive loss of $3.0 million during the period, they secured $1.9 million in non-dilutive funding to support ongoing development. Leadership was strengthened with the appointment of Robert J. Dempsey as CEO, aligning regulatory pathways for future clinical trials.
Read more →OKYOOKYO Pharma Announces Successful Type C Meeting with the FDA
OKYO Pharma announced a successful Type C meeting with the FDA regarding its Phase 2b/3 trial of urcosimod for neuropathic corneal pain. The FDA's alignment on the clinical development program is seen as a significant step forward, potentially addressing a major unmet medical need. The company plans to initiate a 120-patient study in the first half of the year.
Read more →OKYOFDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain
OKYO Pharma has received FDA approval for compassionate use of urcosimod (0.05%) in a patient suffering from neuropathic corneal pain (NCP). This authorization allows access to a treatment option where no FDA-approved therapies exist. Urcosimod's dual mechanism may address both inflammation and nerve dysfunction, providing a new avenue for relief in this debilitating condition.
Read more →OKYO▼ -6.3%on this newsshared move
FDA Authorizes Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain
OKYO Pharma has received FDA authorization for compassionate use of urcosimod (0.05%) to treat a patient with neuropathic corneal pain (NCP). This authorization allows for expanded access to a treatment that currently has no FDA-approved options. The company aims to begin a Phase 2b/3 study of urcosimod later this year, highlighting its potential in addressing this debilitating condition.
Read more →OKYO▲ +7.6%on this news
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer
OKYO Pharma has appointed Robert J. Dempsey as its new CEO, effective immediately. Dempsey brings over two decades of experience in ophthalmology, including successful drug commercialization. He will lead the company as it advances its lead asset, urcosimod, aimed at treating neuropathic corneal pain. The transition is expected to ensure continuity in strategic direction and growth.
Read more →OKYO▲ +8.6%on this news
OKYO Pharma to Ring the Opening Bell at Nasdaq
OKYO Pharma Limited will ring the Opening Bell at Nasdaq to celebrate its advancements in treating neuropathic corneal pain with its lead candidate, urcosimod. The event underscores the company's commitment to addressing unmet medical needs in ocular pain. Recent Phase 2 results have shown promising outcomes for urcosimod, which is currently the only candidate targeting this condition.
Read more →OKYO▲ +8.6%on this newsshared move
OKYO Pharma to Ring the Opening Bell at Nasdaq London and New York, NY
OKYO Pharma Limited will ring the Opening Bell at Nasdaq in New York to celebrate its developments in treatments for neuropathic corneal pain. The event, led by Executive Chairman Gabriele Cerrone, highlights the company's promising Phase 2 trial results for its lead product, urcosimod. This innovative therapy addresses a significant unmet medical need, as no FDA-approved treatments currently exist for this condition. The ceremony will be broadcast live, marking a milestone in OKYO's journey towards improving patient outcomes.
Read more →OKYO▼ -8.3%on this news
OKYO Pharma Announces Chairman and Founder Acquires Shares
OKYO Pharma Limited has announced that its Executive Chairman, Gabriele Cerrone, has acquired an additional 24,551 shares, increasing his total holdings to over 10.5 million shares. The company is focused on developing urcosimod, a treatment for neuropathic corneal pain, which has shown positive results in recent Phase 2 trials. This acquisition reflects Cerrone's confidence in the company's future prospects.
Read more →OKYO▲ +6.9%on this newsshared move
OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain
OKYO Pharma announced positive results from its Phase 2 trial of urcosimod for neuropathic corneal pain. The study demonstrated significant improvements in corneal nerve structure and pain reduction compared to placebo. These findings suggest urcosimod's potential as a first-in-class therapy for this condition, which currently lacks FDA-approved treatments.
Read more →OKYOOKYO Pharma to Present at OIS XV in San Diego London and New York, NY
OKYO Pharma Limited (NASDAQ: OKYO) announced that its CEO, Dr. Gary S. Jacob, will present at the upcoming Ophthalmology Innovation Summit XV in San Diego. The presentation will focus on urcosimod, an investigational drug aimed at treating neuropathic corneal pain (NCP), which currently lacks an FDA-approved therapy. Recent positive results from a Phase 2 trial strengthen the company's commitment to developing effective treatments for this condition. OKYO's participation at the summit will provide opportunities for networking and collaboration with industry leaders.
Read more →OKYOOKYO Pharma to Present at OIS XV in San Diego
OKYO Pharma Limited will present at the Ophthalmology Innovation Summit XV, showcasing its investigational drug urcosimod aimed at treating neuropathic corneal pain (NCP). This condition currently lacks an FDA-approved therapeutic option, highlighting the significance of urcosimod's development. The summit will facilitate networking with industry leaders and partners, bolstering OKYO's efforts to address this unmet medical need. Encouraging results from a prior Phase 2 trial pave the way for a forthcoming multi-center clinical trial involving 120 patients.
Read more →OKYO▲ +6.7%on this news
OKYO Pharma to Present at BIO-Europe 2025 in Vienna
OKYO Pharma Limited will present at the BIO-Europe 2025 conference in Vienna, highlighting its investigational candidate urcosimod. CEO Gary S. Jacob will discuss the company's progress and recent positive clinical trial results for neuropathic corneal pain. The event offers opportunities for partnerships in the biopharma sector.
Read more →OKYO▲ +13.6%on this news
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
OKYO Pharma has announced plans for a multi-center clinical trial of urcosimod, targeting neuropathic corneal pain (NCP). Following positive Phase 2 trial results, where 75% of patients experienced significant pain relief, the company is preparing for a multiple-ascending-dose trial. They are also engaging with the FDA to discuss registration requirements for urcosimod.
Read more →OKYOOKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
OKYO Pharma has secured $1.9 million in non-dilutive funding to enhance the development of urcosimod, its lead candidate for treating neuropathic corneal pain. This funding will help advance clinical milestones and expand research efforts without diluting shareholder equity. CEO Gary S. Jacob highlighted the significance of this funding in addressing an unmet medical need.
Read more →OKYO▲ +16.6%on this newsshared move
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
OKYO Pharma announced promising Phase 2 trial results for urcosimod, a treatment for neuropathic corneal pain (NCP). In the trial, 75% of patients experienced over 80% pain reduction after 12 weeks. The drug showed significant efficacy early in the treatment, and no serious adverse events were reported. OKYO plans to meet with the FDA to discuss future steps.
Read more →OKYO▲ +7.6%on this newsshared move
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduct
OKYO Pharma announced strong results from its Phase 2 clinical trial of urcosimod, a treatment for neuropathic corneal pain (NCP). After 12 weeks, 75% of patients receiving urcosimod experienced over 80% pain relief, with noticeable effects in as soon as 4 weeks. No serious adverse events were reported, indicating a favorable safety profile. The company is preparing to meet with the FDA to discuss subsequent steps for the drug, already designated for Fast Track status to expedite its development.
Read more →OKYO▲ +12.6%on this news· ran to +24% by day 3
OKYO Pharma to Present at the Bio International Convention
OKYO Pharma Limited will present at the Bio International Convention in Boston. CEO Gary S. Jacob will discuss urcosimod, a drug candidate for neuropathic corneal pain, a condition lacking FDA-approved treatments. The presentation will highlight the drug's development and its potential benefits for patients suffering from this debilitating condition.
Read more →OKYO▲ +7.9%on this news· ran to +25% by day 1
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
OKYO Pharma Limited announced that its CEO, Dr. Gary S. Jacob, will present at the 4th Annual GPCRs-Targeted Drug Discovery Summit in Boston on May 22, 2025. The presentation will focus on urcosimod, the company's lead drug candidate aimed at treating neuropathic corneal pain, a condition lacking FDA-approved therapies. Urcosimod has shown potential in clinical trials for both neuropathic corneal pain and dry eye disease.
Read more →OKYOFDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
OKYO Pharma has received Fast Track designation from the FDA for urcosimod, aimed at treating neuropathic corneal pain (NCP). This designation is intended to expedite the development and review process for therapies addressing serious conditions. Neuropathic corneal pain is currently without an FDA-approved treatment, highlighting the urgency of this development. The company is committed to advancing urcosimod through clinical trials and regulatory review.
Read more →OKYOOKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
OKYO Pharma has announced plans to accelerate the clinical development of urcosimod for treating neuropathic corneal pain (NCP) following the early closure of its Phase 2 trial. The trial, conducted at Tufts Medical Center, involved 17 patients who completed the study. OKYO aims to analyze the data and meet with the FDA to discuss further development plans. Urcosimod has previously demonstrated favorable safety and tolerability.
Read more →OKYOOKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain Urcosimod phase 2 trial treating Neuropathic Corneal Pain ("NCP") patients was initiated in October 2024 a
OKYO Pharma has announced plans to expedite the clinical development of Urcosimod to treat Neuropathic Corneal Pain (NCP) following the early closure of its phase 2 trial. The trial, conducted at Tufts Medical Center, involved 17 patients suffering from chronic pain, and the decision to close it was driven by a desire to quickly access data for planning further studies. Despite the early closure, the company is experiencing strong interest from potential future trial participants and aims to meet with the FDA to discuss the next steps for Urcosimod's development.
Read more →OKYO▼ -5.9%on this news
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod
OKYO Pharma announced that urcosimod has demonstrated stability for over two and a half years in single-use ampoules. This stability is crucial for meeting FDA requirements for a New Drug Application. The drug is currently undergoing a Phase 2b clinical trial for neuropathic corneal pain, with promising results from previous studies in treating dry eye disease.
Read more →OKYOOKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain
OKYO Pharma has applied for Fast Track designation from the FDA for urcosimod, aimed at treating neuropathic corneal pain, a condition currently lacking an effective FDA-approved therapy. The Fast Track designation could expedite the drug's development and review process. Urcosimod has demonstrated potential in clinical trials, indicating it may significantly improve treatment options for affected patients.
Read more →OKYOOKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain London and New York, NY
OKYO Pharma Limited has announced the filing for Fast Track designation from the FDA for its drug urcosimod to treat neuropathic corneal pain, a condition that currently lacks an approved therapy. The Fast Track designation aims to expedite the development of drugs addressing serious conditions, and the company is optimistic that urcosimod could redefine treatment paradigms. Urcosimod, a novel chemerin peptide agonist, has shown promising results in clinical trials for anti-inflammatory and pain-reducing effects. This milestone is a significant step toward meeting the urgent needs of patients suffering from this debilitating condition.
Read more →OKYOOKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod
OKYO Pharma has announced that its lead asset, OK-101, has been assigned the USAN name urcosimod. This designation reflects the company's commitment to developing therapies for unmet medical needs in ophthalmology. Urcosimod is currently undergoing a Phase 2 clinical trial for neuropathic corneal pain, a condition lacking FDA-approved treatments. The drug's dual anti-inflammatory and analgesic properties position it as a promising therapeutic option.
Read more →OKYOOKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod London and New York, NY
OKYO Pharma Limited has announced that its lead drug candidate, OK-101, has officially received the United States Adopted Name 'urcosimod'. This designation highlights the company’s commitment to addressing unmet medical needs in ophthalmology, particularly in treating neuropathic corneal pain and dry eye disease. Urcosimod is currently undergoing Phase 2 clinical trials, where it has demonstrated promising anti-inflammatory and pain-reducing properties. The drug's innovative lipid-conjugated design sets it apart in the development of new therapeutic options for ocular conditions.
Read more →OKYOOKYO Pharma Announces Chairman and CEO Acquire Shares
OKYO Pharma Limited has announced that CEO Gary S. Jacob and Executive Chairman Gabriele Cerrone have purchased shares of the company at $1.04 each. Jacob acquired 10,000 shares, while Cerrone's entity bought 20,000 shares, increasing his total ownership to nearly 29% of the company. OKYO is focused on developing therapies for neuropathic corneal pain and inflammatory dry eye disease.
Read more →OKYOOKYO Pharma Announces Chairman and CEO Acquire Shares London and New York, NY
OKYO Pharma Limited announced that its CEO Gary S. Jacob and Executive Chairman Gabriele Cerrone have bought a total of 30,000 ordinary shares of the company at $1.04 per share. This purchase reflects a strong commitment from the management as the company continues developing therapies for neuropathic corneal pain and inflammatory dry eye disease, markets with significant unmet needs. Alongside their share purchases, OKYO is advancing its Phase 2 trials for its leading candidates targeting these ocular conditions.
Read more →OKYOOKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter
OKYO Pharma Limited is on track to complete enrollment for its Phase 2a trial of OK-101 for neuropathic corneal pain by the end of Q2 2025. The trial aims to provide significant data for a condition lacking FDA-approved treatments. The company also reported positive results from a Phase 2b trial for dry eye disease, showcasing the efficacy of OK-101. Financially, OKYO has improved its asset base and reduced losses compared to the previous year.
Read more →OKYOOKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter London and New York, NY
OKYO Pharma Limited announced plans to complete the enrollment of its Phase 2a trial for treating neuropathic corneal pain (NCP) by the end of the second quarter of 2025, with top-line data expected in the fourth quarter. The company has received FDA approval for its investigational new drug, OK-101, marking a significant step in addressing an ocular condition lacking approved treatments. Furthermore, recent positive data from the Phase 2b trial suggests a promising clinical development path for the treatment of inflammatory dry eye disease. The trial is being conducted under the leadership of Dr. Pedram Hamrah, a recognized expert in ocular pain.
Read more →OKYOOKYO Pharma Receives $1.4 Million in Non-Dilutive Funding
OKYO Pharma has secured $1.4 million in non-dilutive funding to enhance its research and development efforts, particularly for its lead program, OK-101, aimed at treating neuropathic corneal pain (NCP). This funding is expected to help advance their innovative pipeline without impacting shareholder value. The company remains focused on addressing critical unmet medical needs in ophthalmic diseases.
Read more →OKYOOKYO Pharma Receives $1.4 Million in Non-Dilutive Funding London and New York, NY
OKYO Pharma Limited announced the receipt of $1.4 million in non-dilutive funding, which will enhance its capabilities in developing treatments for neuropathic corneal pain and dry eye disease. This financial injection is expected to support ongoing research initiatives and the advancement of OKYO's lead program, OK-101. The company emphasizes its commitment to maintaining fiscal responsibility while addressing significant unmet medical needs in ophthalmic diseases. Additionally, OK-101 is currently being evaluated in clinical trials for its efficacy in treating these conditions.
Read more →OKYOOKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference
OKYO Pharma Limited announced its participation in the 4th Annual BTIG Ophthalmology Conference on December 2, 2024, where CEO Gary S. Jacob will engage in discussions and a fireside chat. The presentation will focus on their advancements in treating neuropathic corneal pain (NCP) and inflammatory dry eye disease (DED) with their drug candidate, OK-101. This drug has shown anti-inflammatory and pain-reducing effects in trials and represents a significant step in addressing conditions currently lacking FDA-approved treatments.
Read more →OKYOOKYO Pharma to Participate at the 4 th Annual BTIG Ophthalmology Conference London and New York, NY
OKYO Pharma Limited will participate in the 4th Annual BTIG Ophthalmology Conference on December 2, 2024, featuring CEO Gary S. Jacob in one-on-one meetings and a fireside chat. The conference will showcase over 20 medical technology and biotechnology companies discussing developments in ophthalmic medical technologies and therapeutics. OKYO is notable for developing therapies for neuropathic corneal pain and dry eye disease, focusing on the innovative drug candidate OK-101, which has shown promise in clinical trials for these conditions.
Read more →OKYOOKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference
OKYO Pharma Limited will present at the 10th International Tear Film & Ocular Surface Society Conference in Venice from October 30 to November 2, 2024. The presentation will focus on the efficacy and safety results of the Phase 2 trial of OK-101 for treating dry eye disease. The company is also initiating a Phase 2 trial for neuropathic corneal pain. CEO Dr. Gary S. Jacob expressed excitement about sharing clinical findings.
Read more →OKYOOKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference London and New York, NY
OKYO Pharma Limited is set to present at the 10th International Tear Film & Ocular Surface Society Conference in Venice from October 30 to November 2, 2024. The company will share results from its recent Phase 2 trial of OK-101, aimed at treating dry eye disease and neuropathic corneal pain. CEO Dr. Gary S. Jacob emphasized the importance of finding lasting treatments for patients suffering from these debilitating conditions. The conference will feature one-on-one discussions regarding the clinical findings and ongoing studies at Tufts Medical Center.
Read more →OKYO▲ +19.4%on this news
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain
OKYO Pharma has announced the dosing of the first patient in its Phase 2 clinical trial for OK-101, aimed at treating neuropathic corneal pain (NCP). This trial is notable as it is the first to enroll patients specifically diagnosed with NCP and is designed as a randomized, placebo-controlled study. OK-101 is the first drug candidate to receive an IND from the FDA for this condition, addressing a significant unmet need in ocular pain management.
Read more →OKYO▲ +19.4%on this newsshared move
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in
OKYO Pharma has announced that the first patient has been dosed in a Phase 2 clinical trial aiming to investigate the efficacy of OK-101, a treatment for neuropathic corneal pain (NCP). This trial is notable as OK-101 is the first drug candidate to receive FDA IND status specifically for NCP, a condition currently lacking FDA-approved therapies. The study, designed as a randomized, placebo-controlled trial, will enroll 48 patients over a 12-week period. The Principal Investigator, Dr. Pedram Hamrah, emphasizes the critical need for effective therapies to alleviate the debilitating pain associated with NCP.
Read more →OKYOOKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain
OKYO Pharma has initiated a Phase 2 clinical trial for OK-101 to treat neuropathic corneal pain (NCP), an orphan disease with no approved therapies. The trial will enroll 48 patients and is designed to measure pain relief using a Visual Analog Scale. OK-101 has previously demonstrated significant efficacy in treating dry eye disease, suggesting potential benefits for NCP patients.
Read more →OKYOOKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain Neuropathic corneal pain (NCP) is listed in the National Organization for Rare Disorders (NORD) as an orphan disease O
OKYO Pharma has initiated a Phase 2 clinical trial for OK-101 aimed at treating patients with Neuropathic Corneal Pain (NCP), an orphan disease with no FDA-approved therapies. The trial will enroll 48 patients and is designed to assess pain relief using a placebo-controlled, double-masked methodology. This study follows previous successful trials of OK-101 in addressing dry eye disease symptoms. The trial is particularly significant given the unmet medical need associated with NCP, which often causes debilitating ocular pain.
Read more →OKYO▲ +6.8%on this news
OKYO Pharma Announces Chairman Acquires Shares
OKYO Pharma Limited announced that Executive Chairman Gabriele Cerrone acquired an additional 50,000 shares, increasing his stake to 29.12%. The company is developing innovative therapies for dry eye disease and neuropathic corneal pain, with the drug OK-101 demonstrating anti-inflammatory efficacy in trials. A recently completed Phase 2 trial for OK-101 to treat dry eye disease has shown statistical significance, and plans for a Phase 2 trial targeting neuropathic corneal pain are underway.
Read more →OKYO▲ +6.8%on this news
OKYO Pharma Announces Chairman Acquires Shares London and New York, NY
OKYO Pharma Limited (NASDAQ: OKYO) announced that its Executive Chairman, Gabriele Cerrone, has acquired 50,000 shares, increasing his stake to 29.12% of the company. The firm is developing treatments for inflammatory dry eye disease and associated conditions, with OK-101 showing promising results in a Phase 2 trial. Future plans include launching a Phase 2 trial for treating neuropathic corneal pain.
Read more →OKYO▲ +14.7%on this news· ran to +26% by day 3
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
OKYO Pharma has been granted U.S. Patent No. 12,053,501 for OK-101, a treatment for dry eye disease (DED). This patent enhances the company's intellectual property and supports its commitment to developing innovative therapies for ocular pain and inflammation. OK-101 has demonstrated efficacy in clinical trials, indicating its potential in addressing significant unmet medical needs.
Read more →OKYO▲ +14.7%on this news· ran to +26% by day 3shared move
OKYO Pharma Granted U.S. Patent Covering OK-101's Potential for Treating Symptoms of Dry Eye Disease London and New York, NY
OKYO Pharma Limited has announced the grant of a U.S. Patent No. 12,053,501 for its drug candidate OK-101, which targets symptoms of dry eye disease. This patent strengthens the company's intellectual property and underlines the therapeutic potential of OK-101. The drug has demonstrated positive results in a Phase 2 trial and is designed to enhance patient outcomes for those suffering from ocular pain and inflammation. OKYO is also exploring partnerships to expedite the development and commercialization of its therapies.
Read more →OKYOOKYO Pharma CEO Interview to Air on Bloomberg TV
OKYO Pharma Limited has announced that CEO Dr. Gary S. Jacob will be featured on Bloomberg TV's RedChip Small Stocks, Big Money show on August 24. The interview will focus on ongoing developments at OKYO, including the recent Phase 2 trial results of OK-101 for Dry Eye Disease (DED) and future plans for treating Neuropathic Corneal Pain (NCP). The lead candidate, OK-101, demonstrated significant efficacy and safety in the trial. The company remains well-positioned in the ocular therapeutics market with its strong patent portfolio and experienced leadership.
Read more →OKYOOKYO Pharma CEO Interview to Air on Bloomberg TV London and New York, NY
OKYO Pharma Limited announced that an interview with CEO Dr. Gary S. Jacob will air on Bloomberg TV on August 24. The company is focused on developing therapies for dry eye disease and neuropathic corneal pain, with their lead candidate OK-101 showing promising results in recent trials. The Phase 2 trial demonstrated improvements in symptoms within 15 days, maintaining a favorable safety profile. OKYO also emphasizes its strong patent protection and experienced management team as key factors for future growth in the ophthalmology sector.
Read more →OKYOOKYO Pharma Participates in H.C. Wainwright 4 th Annual Ophthalmology Virtual Conference London and New York, NY
OKYO Pharma Limited (NASDAQ: OKYO) announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024. The company is developing innovative therapies for inflammatory dry eye disease and neuropathic corneal pain, focusing on its lead candidate, OK-101. Recently, OK-101 demonstrated statistical significance in a completed Phase 2 trial for treating dry eye disease. The firm aims to address significant unmet medical needs in ocular health.
Read more →OKYOOKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
OKYO Pharma Limited announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15th, 2024. The company is focusing on innovative ocular therapies, particularly for inflammatory dry eye disease and neuropathic corneal pain. Their drug candidate, OK-101, has shown promising results in a completed Phase 2 clinical trial. The method employs a unique lipid anchor to enhance the drug’s effectiveness within the eye.
Read more →OKYO▲ +5.3%on this news
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
OKYO Pharma has been granted a European patent for its OK-101 chemerin analogs, which are aimed at treating inflammatory dry eye disease and neuropathic corneal pain. This patent enhances the company's intellectual property portfolio and reflects its commitment to developing innovative therapies. OK-101 has shown efficacy in clinical trials, positioning OKYO for future advancements.
Read more →OKYO▲ +5.3%on this newsshared move
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use London and New York, NY
OKYO Pharma Limited announced the granting of a European patent for its novel OK-101 chemerin analogs, aiming to address ocular inflammatory and pain conditions. This patent strengthens the company's intellectual property portfolio, highlighting its commitment to developing innovative therapies for unmet medical needs, particularly in inflammatory dry eye disease. OK-101 shows promise based on favorable results from a Phase 2 trial, which exhibited statistical significance across multiple endpoints. The company plans to explore further trials and strategic partnerships to advance its therapies.
Read more →OKYO▲ +25.6%on this news· ran to +36% by day 1
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
OKYO Pharma plans to initiate a Phase 2 clinical trial for OK-101, targeting neuropathic corneal pain (NCP), expected to begin in Q3 2024. This trial follows promising results from earlier studies showing significant pain relief in related conditions. OK-101 is noted for being the first drug to receive FDA IND clearance specifically for NCP, addressing a critical unmet medical need.
Read more →OKYO▲ +25.6%on this news· ran to +36% by day 1shared move
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101 Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IN
OKYO Pharma plans to initiate a Phase 2 clinical trial for OK-101, targeting neuropathic corneal pain (NCP), with a planned start in Q3 2024. This trial will be a randomized, placebo-controlled study at Tufts Medical Center, aiming to evaluate the drug's effectiveness based on previous statistical evidence of pain relief in patients with dry eye disease. OK-101 represents a significant advancement in addressing an unmet medical need for NCP, as there are currently no FDA-approved treatments for this painful ocular condition.
Read more →OKYOOKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
OKYO Pharma has reported promising results from its Phase 2 trial of OK-101 for dry eye disease, showing a 68% improvement in responder rates for patients meeting both ocular pain and conjunctival staining endpoints. The trial indicates a favorable tolerability profile for OK-101, paving the way for future studies. The company aims to address the unmet needs of patients suffering from dry eye disease.
Read more →OKYOOKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease - Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining "sign" and o
OKYO Pharma announced encouraging categorical data from its OK-101 Phase 2 trial for treating dry eye disease (DED), showing a 68% improvement in responder rates compared to a placebo. The trial's findings highlight conjunctival staining and ocular pain as potential co-primary endpoints for future studies. The company noted a favorable tolerability profile for the OK-101 eyedrop solution, which is designed to address inflammatory dry eye and neuropathic pain. This data positions OKYO to advance towards further clinical trials and FDA interactions.
Read more →OKYOOKYO Pharma Announces Participation in May 2024 Investor Conferences
OKYO Pharma Limited has announced its participation in two investor conferences in May 2024. The Aegis Capital Virtual Healthcare Conference will take place on May 8, followed by the Citizens JMP Securities Life Sciences Conference on May 13. CEO Gary Jacob, PhD, will present at both events, highlighting the company's innovative ocular therapies.
Read more →OKYOOKYO Pharma Announces Participation in May 2024 Investor Conferences London and New York, NY
OKYO Pharma Limited announced its participation in investor conferences scheduled for May 2024, highlighting its focus on developing ocular therapies for inflammatory dry eye disease and neuropathic corneal pain. The company is actively involved in clinical trials, including a recently completed Phase 2 trial for dry eye disease and plans for a Phase 2 trial for neuropathic corneal pain. This participation aims to boost the company's profile and attract potential investors in the biopharmaceutical sector.
Read more →OKYOOKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO) London and New Yo
OKYO Pharma Limited has announced an upcoming presentation of Phase 2 data for its drug OK-101, aimed at treating dry eye disease. The presentation is scheduled for May 3, 2024, as part of the Dry Horizons Symposium, hosted by the Association for Research in Vision and Ophthalmology in Seattle. This conference is expected to highlight the significant challenges faced in the dry eye market and explore new therapeutic opportunities. OKYO is also planning a Phase 2 trial to address neuropathic corneal pain, which currently lacks FDA-approved treatments.
Read more →OKYOOKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
OKYO Pharma has announced the rescheduling of its Key Opinion Leader event on the Phase 2 trial of OK-101 in dry eye disease to May 2024. The delay is intended to incorporate additional analyses of clinical data. The company will also present at the Dry Horizons Symposium on May 3, 2024, focusing on advancements in dry eye research.
Read more →OKYOOKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024 London and New York, NY
OKYO Pharma Limited has announced the rescheduling of a Key Opinion Leader event focused on dry eye disease to May 2024. This new date will allow the company to include additional analyses of their clinical data related to the Phase 2 trial of OK-101, a novel treatment for the condition. The event will coincide with the Dry Horizons Symposium, where industry leaders will discuss innovative solutions and advancements in dry eye research. OK-101 has demonstrated positive outcomes in previous trials and aims to address significant unmet needs in the ocular health market.
Read more →OKYOOKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery London and New York, NY
OKYO Pharma Limited has announced that it will present Phase 2 data for its dry eye disease treatment, OK-101, at Eyecelerator 2024, an event supported by the American Society for Cataract and Refractive Surgery. The presentation will take place on April 4, 2024, in Boston, MA, and aims to showcase advancements in ocular therapies. This event provides networking opportunities and highlights innovative trends in eye care, indicating a commitment to advancing treatments in this area.
Read more →OKYOLondon and New York, NY
OKYO Pharma Limited has reported interim results for the six months ending September 30, 2023, highlighting the positive completion of its Phase 2 trial for OK-101 aimed at treating dry eye disease and neuropathic corneal pain. The trial showed statistically significant improvements in several ocular symptoms, and the company received FDA approval to test OK-101 for neuropathic corneal pain. However, the financial statement reflects challenges, as total assets and cash on hand have decreased, leading to an increased comprehensive loss for the period.
Read more →OKYO▼ -12.8%on this news
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event -Phase 2 OK-101 efficacy data to be released
OKYO Pharma Limited announced the upcoming release of new efficacy data from its Phase 2 trial of OK-101 for dry eye disease, set for March 22, 2024. The trial demonstrated promising results with significant drug effects observed as early as 15 days post-dosing. Additionally, the company will host a Key Opinion Leader event to discuss the findings in detail. Plans for advancing OK-101 into Phase 3 clinical trials are also in place, targeting both dry eye disease and neuropathic corneal pain.
Read more →OKYO▼ -12.8%on this news
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101 Ocular Pain Relief
OKYO Pharma announced that its Phase 2 trial for OK-101 achieved statistical significance in improving multiple signs and symptoms of dry eye disease, including ocular pain relief. Significant improvements were observed in various symptoms such as tearing and blurred vision as early as Day 15. The trial also highlighted the drug’s high tolerability and favorable safety profile, with no serious adverse events reported. These promising results pave the way for potential Phase 3 trials aimed at treating this multi-billion-dollar market.
Read more →OKYOOKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
OKYO Pharma will host a Key Opinion Leader event on April 9, 2024, to discuss new efficacy data from its Phase 2 trial of OK-101 for dry eye disease. The trial results will be announced on March 22, 2024. Experts Jay Pepose and Anat Galor will present findings and address the unmet need for effective treatments in this area.
Read more →OKYOOKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial - Phase 2 OK-101 efficacy data to be released March 22nd, 2024- -KOL Event to be held on April 9th, 20
OKYO Pharma Limited is set to host a Key Opinion Leader event discussing new efficacy data from its Phase 2 trial of OK-101 for the treatment of dry eye disease on April 9, 2024. The results, to be announced on March 22, 2024, indicate statistically significant improvements in FDA-recognized efficacy endpoints early in the treatment. The event will feature renowned experts who will review the advanced findings and the unmet needs in the ocular pain management market. OK-101 aims to provide an innovative therapeutic solution for inflammatory dry eye disease, which is currently a multi-billion-dollar market.
Read more →OKYO▲ +20%on this newsshared move
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
OKYO Pharma Limited announced the upcoming release of comprehensive efficacy data from its Phase 2 trial of the ocular therapy OK-101 for dry eye disease on March 22, 2024. The trial demonstrated significant improvements in key efficacy endpoints, prompting the company to host a Key Opinion Leader event to explore the findings. The CEO indicated plans to advance OK-101 into Phase 3 trials next year and noted its dual focus on treating both dry eye disease and neuropathic corneal pain, for which IND clearance has been obtained for clinical studies.
Read more →OKYO▲ +19.6%on this news
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
OKYO Pharma has received FDA approval for its first Investigational New Drug (IND) application for OK-101, aimed at treating neuropathic corneal pain (NCP). The Phase 2 clinical trial is set to begin in Q2 2024, designed as a randomized, placebo-controlled study. This approval represents a significant advancement in addressing an unmet medical need for patients suffering from NCP.
Read more →OKYO▲ +19.6%on this newsshared move
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropat
OKYO Pharma has received FDA approval for its Investigational New Drug (IND) application for OK-101, intended for treating neuropathic corneal pain (NCP), an ocular condition with no FDA-approved therapies available. The Phase 2 clinical trial is set to begin in the second quarter of 2024, employing a randomized, placebo-controlled design. Approximately 54 patients will participate in the study, which aims to validate the drug's efficacy in alleviating NCP symptoms. The approval marks a significant milestone for OKYO Pharma as it expands its therapeutic portfolio.
Read more →OKYOOKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board London and New York, NY
OKYO Pharma Limited has announced the addition of three distinguished ophthalmologists to its Scientific Advisory Board, enhancing its expertise in treating inflammatory dry eye disease and neuropathic corneal pain. The company is following positive results from its Phase 2 trial of the drug OK-101, which aims to address these conditions that currently lack FDA-approved therapies. The new advisory board members, with extensive backgrounds in ocular health, will support OKYO's clinical development efforts. A conference call is planned for Q1 2024 to discuss further trial data.
Read more →OKYOOKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease Statistically significant dru
OKYO Pharma announced positive results for OK-101 in its Phase 2 trial, showing statistically significant improvements in dry eye symptoms and signs. The drug demonstrated a favorable safety profile and establishes a clear path for advancing to Phase 3 trials. The results indicate promise not only for treating dry eye disease but potentially for corneal neuropathic pain as well. Moreover, the improvements were observed as early as 15 days post-dosing.
Read more →OKYO▲ +7.7%on this newsshared move
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
OKYO Pharma Limited will present at the Biotech Showcase Conference in San Francisco from January 8-10, 2024. CEO Gary S. Jacob will discuss the clinical development status of OK-101, which recently completed a phase 2 trial for treating dry eye disease. The conference aims to foster investment and partnership opportunities in the biotech sector.
Read more →OKYO▲ +9.6%on this newsshared move
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024 London and New York, NY
OKYO Pharma Limited announced its participation in the Biotech Showcase Conference in San Francisco scheduled for January 8-10, 2024. The company will present its clinical development progress on OK-101, a treatment for inflammatory dry eye disease, following the completion of a phase 2 trial involving 240 patients. The event serves as a key platform for networking and partnership opportunities in the biotechnology sector, drawing participation from global investors and executives.
Read more →OKYOOKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
OKYO Pharma has announced the completion of the final protocol visit for the last patient enrolled in its Phase 2 clinical trial of OK-101 for treating dry eye disease. The trial, which included 240 patients, is on track to release top-line efficacy and safety data in December 2023. OK-101 has demonstrated dual-action properties in pre-clinical studies, and the company is optimistic about its potential to address this common condition.
Read more →OKYOOKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit Top-line Efficacy and Safety Data on Track for Release in December 2023 London and
OKYO Pharma announced that the last patient has completed the final visit in the Phase 2 clinical trial for OK-101, aimed at treating dry eye disease (DED). This trial, which includes 240 patients, is double-blind and placebo-controlled, focusing on evaluating the drug's efficacy and safety. The company anticipates the release of top-line data by December 2023, following final data analysis and FDA feedback. This represents a pivotal step in assessing OK-101's therapeutic potential for millions suffering from DED.
Read more →OKYOOKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction
OKYO Pharma has announced a cash raise of $5.84 million through a registered direct offering of shares. The offering includes the extinguishment of $4.20 million in payables, significantly reducing the company's liabilities. The funds will primarily be used for clinical development and general corporate purposes. The offering is expected to close on November 1, 2023.
Read more →OKYOOKYO Pharma Announces $5.84 Million cash raise and payables reduction Pricing of a registered direct offering for $1.64M of 1,092,600 ordinary shares at an offering price of $1.50 per ordinary share Simultaneous extingui
OKYO Pharma Limited announced a successful registered direct offering, raising $5.84 million through the issuance of ordinary shares at $1.50 each. In addition to this, the company will extinguish $4.20 million of payables, significantly improving its financial obligations. The funds from the offering will primarily be allocated for the clinical development of the company's product candidates targeting inflammatory dry eye disease and neuropathic corneal pain. The offering's completion is anticipated around November 1, 2023, contingent on customary closing conditions.
Read more →OKYO▼ -10.6%on this news· ran to -24% by day 3
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)
OKYO Pharma has filed an IND application for OK-101 to treat Neuropathic Corneal Pain (NCP), a condition with no FDA-approved therapies. The company plans to initiate a 40-patient open-label trial in Q1 2024, led by Dr. Pedram Hamrah at Tufts Medical Center. OK-101 is also undergoing a Phase 2 trial for dry eye disease, with results expected in December 2023.
Read more →OKYO▼ -10.6%on this news· ran to -24% by day 3shared move
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain ("NCP") OKYO plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr P
OKYO Pharma Limited has announced the filing of an IND application for OK-101, aimed at treating Neuropathic Corneal Pain (NCP). The company plans to conduct a 40-patient open-label clinical trial starting in Q1 2024, led by Dr. Pedram Hamrah, a recognized expert in the field. This trial follows the current Phase 2 study of OK-101 for dry eye disease, with results expected in December 2023. The development of OK-101 addresses a significant gap in available treatments for NCP, highlighting the company's commitment to advanced ocular therapies.
Read more →OKYO▼ -9.1%on this news· ran to -33% by day 3shared move
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease (“DED”)
OKYO Pharma has reported positive safety data from its ongoing Phase 2 clinical trial of OK-101 for treating dry eye disease (DED). The trial has seen over 95% of patients complete 4 weeks of dosing, with a low dropout rate of 5.4%. The company anticipates releasing top-line efficacy and safety data in December 2023.
Read more →OKYO▼ -9.1%on this news· ran to -33% by day 3shared move
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED") Over 95% of randomized DED patients have completed 4 weeks of dosing in the planned 12-wee
OKYO Pharma has reported positive safety data for its ongoing Phase 2 trial of the drug candidate OK-101 aimed at treating dry eye disease (DED). With 95% of patients completing four weeks of dosing, the trial has shown a 5.4% dropout rate unrelated to side effects. The company is encouraged by the safety profile observed so far and expects to release top-line efficacy and safety data in December 2023. The trial includes 240 patients to assess OK-101’s safety and tolerability.
Read more →OKYO▲ +12.4%on this news
OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares
OKYO Pharma Limited has successfully closed a registered direct offering of 2,666,670 ordinary shares, raising $4 million. The offering, priced at $1.50 per share, was conducted without an underwriter. The proceeds will primarily be used for clinical development and general corporate purposes. The offering was made under a previously filed shelf registration statement.
Read more →OKYO▲ +12.4%on this newsshared move
OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares London and New York, NY
OKYO Pharma Limited announced the successful closing of a $4.0 million registered direct offering of 2,666,670 ordinary shares at $1.50 each. This funding is intended for clinical development of its product candidates and general corporate purposes. The offering was executed without an underwriter and is part of a shelf registration with the SEC. The company cautions investors about inherent risks and uncertainties that could affect future performance.
Read more →OKYOOKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares
OKYO Pharma Limited has announced a registered direct offering of 2,666,667 ordinary shares priced at $1.50 each, aiming to raise $4.0 million. The funds will primarily support clinical development and general corporate purposes. The offering is set to close on or about September 15, 2023, pending customary conditions.
Read more →OKYO▲ +9.3%on this news· ran to +23% by day 1shared move
OKYO Pharma Limited Announces Withdrawal of Public Offering
OKYO Pharma Limited has announced the withdrawal of its proposed public offering of ordinary shares, citing changing market conditions. The company has also terminated Freedom Capital Markets as its underwriter. This decision raises concerns about the company's financial stability and ability to secure funding in the current market environment.
Read more →OKYO▼ -10.6%on this newsshared move
OKYO Pharma Limited Announces Withdrawal of Public Offering LONDON and
OKYO Pharma Limited announced the withdrawal of its public offering of ordinary shares on September 14, 2023. This decision comes as a response to changing market conditions, which may indicate financial difficulties for the company. Additionally, the termination of Freedom Capital Markets as underwriter raises concerns about the company's ability to attract investment in the future. The announcement signals uncertainty in OKYO's financial strategies as the company seeks to develop treatments for dry eye disease.
Read more →OKYO▼ -10.6%on this newsshared move
OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares London and New York, NY
OKYO Pharma Limited has announced the pricing of a registered direct offering of 2,666,667 ordinary shares at $1.50 each, expected to raise approximately $3.95 million. The funds will primarily support the clinical development of its product candidates, enhance general corporate purposes, and provide working capital. The offering is anticipated to close by September 15, 2023, subject to customary closing conditions. The company is focusing on developing treatments for dry eye disease and has successfully filed necessary documentation with the SEC for the offering.
Read more →OKYOOKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease
OKYO Pharma has completed enrollment in its Phase 2 clinical trial for OK-101, aimed at treating dry eye disease. A total of 240 patients were enrolled, with top-line data anticipated in December 2023. The trial is structured to evaluate the safety and efficacy of OK-101, which has shown promise in preliminary studies.
Read more →OKYOOKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease Full enrollment achieved on September 6 th with a total of 240 patients enrolled in study Top-line data planned for release in
OKYO Pharma Limited has completed the enrollment of 240 patients in its Phase 2 clinical trial for OK-101, a treatment aimed at addressing dry eye disease. The trial, which is randomized, double-masked, and placebo-controlled, is crucial for evaluating the safety and efficacy of the drug. The full study results are anticipated to be released in December 2023, following the last patient's visit scheduled for late November. This trial positions OKYO Pharma on the path to potentially register OK-101 as a treatment in a market with significant unmet needs.
Read more →OKYO▼ -17.8%on this news· ran to -35% by day 3
OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)
OKYO Pharma has successfully enrolled 90% of participants in its 240-patient Phase 2 clinical trial for OK-101, aimed at treating dry eye disease. The trial, which began in May 2023, is expected to complete enrollment by early September and release top-line data by the end of 2023. The study is designed to evaluate the drug's safety and efficacy.
Read more →OKYO▼ -17.8%on this news· ran to -35% by day 3shared move
OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease ("DED") Full enrollment anticipated by first week of September OKYO on schedule to release top-line data before
OKYO Pharma has successfully enrolled 90% of patients in its 240-patient Phase 2 clinical trial for the drug OK-101 aimed at treating dry eye disease (DED). Full enrollment is expected by the first week of September 2023, with top-line data anticipated to be released by the end of the year. The trial is designed to evaluate the safety and efficacy of OK-101 and is a critical step toward potential registration of the drug. The company is working with Ora Inc. to manage the trial and appreciates the contributions of participating clinicians and patients.
Read more →OKYO▲ +8.6%on this news· ran to -29% by day 3shared move
OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule
OKYO Pharma Limited has successfully regained compliance with Nasdaq's minimum market value rule after previously falling below the required $35 million threshold. The company maintained its market value above this level for the necessary 10 consecutive business days, achieving compliance on August 28, 2023. This development is significant for OKYO as it ensures its continued listing on the Nasdaq Capital Market.
Read more →OKYO▲ +8.6%on this news· ran to -29% by day 3shared move
OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule New York and London
OKYO Pharma Limited has announced that it has regained compliance with Nasdaq's minimum market value rule after previously falling below the $35 million threshold. The company confirmed it has maintained the minimum market value for over ten consecutive business days as of August 28, 2023. This compliance is crucial for its continued inclusion on the Nasdaq Capital Market. OKYO Pharma is focusing on developing treatments for dry eye disease, which addresses a substantial unmet need in a lucrative market.
Read more →OKYO▲ +14.1%on this news
OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023
OKYO Pharma Limited reported its annual results for the year ending March 31, 2023, highlighting progress in its lead program, OK-101, for treating dry eye disease. The company has initiated a phase 2 clinical trial and plans to explore treatment for neuropathic corneal pain. However, the financial results showed a loss of $13.7 million, with increased R&D expenses.
Read more →OKYOOKYO Pharma Limited Reports Annual Results for the Twelve Months Ended
OKYO Pharma Limited reported its annual financial results for the year ending March 31, 2023, revealing progress in its lead program, OK-101, intended to treat dry eye disease (DED). The company has initiated a phase 2 clinical trial for OK-101, focusing on its safety and efficacy with expectations of significant patient enrollment this summer. Furthermore, OKYO plans to expand its research to address neuropathic corneal pain, which currently lacks an FDA approved treatment. The CEO expressed optimism about the drug's unique properties and commitment to advancing ocular health solutions.
Read more →OKYO▼ -15%on this news· ran to -28% by day 3shared move
OKYO Pharma Announces Proposed Public Offering of Ordinary Shares
OKYO Pharma Limited announced its intention to conduct a public offering of ordinary shares to fund the clinical development of its product candidates, including OK-101 for dry eye disease. The offering is underwritten by ThinkEquity and is subject to market conditions. The company aims to address the unmet needs in the dry eye market, which is valued in the billions.
Read more →OKYO▼ -15%on this news· ran to -28% by day 3shared move
OKYO Pharma Limited Receives Nasdaq Deficiency Notice
OKYO Pharma Limited has received a deficiency notice from Nasdaq due to its market value falling below the required $35 million for 30 consecutive business days. The company has a 180-day period to regain compliance, or it may face delisting. The notice does not immediately affect the listing status of OKYO's shares.
Read more →OKYO▲ +17%on this newsshared move
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center
OKYO Pharma has announced plans to initiate a Phase 2 clinical trial for OK-101, targeting neuropathic corneal pain (NCP). This trial, involving 40 patients, will be conducted at Tufts Medical Center under the leadership of Dr. Pedram Hamrah. The trial aims to evaluate the safety and efficacy of OK-101, which is also being tested for dry eye disease, with results expected by the end of 2023.
Read more →OKYO▲ +17%on this newsshared move
OKYO Pharma Limited Receives Nasdaq Deficiency Notice New York
OKYO Pharma Limited has received a deficiency notice from Nasdaq due to its ordinary shares closing below the required $35 million market value for continued listing. The company has a compliance period of 180 days to rectify this situation. Should it fail to regain compliance by the deadline of January 22, 2024, OKYO may face delisting but can appeal the decision. The company emphasizes its focus on treating dry eye disease and the pressing unmet medical need in this market.
Read more →OKYO▲ +17%on this newsshared move
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain ("NCP") Following Announcement of Clinical Trial Agreement with Tufts Medical Center OKYO plans a 40-patient OK-101 open-label clinical tr
OKYO Pharma has announced plans to initiate a Phase 2 trial of its investigational drug OK-101 for treating neuropathic corneal pain (NCP). In partnership with Tufts Medical Center, the trial will evaluate the safety and efficacy of OK-101, following its current Phase 2 study for dry eye disease. The trial, enrolling 40 patients, is set to launch in Q4 2023, with enrollment commencing after IND approval. The collaborative effort highlights the drug's potential as a non-opioid treatment option for this debilitating condition which currently lacks FDA-approved therapies.
Read more →OKYO▲ +17%on this newsshared move
OKYO Pharma Announces Proposed Public Offering of Ordinary Shares London and New York, NY
OKYO Pharma Limited has announced its intention to conduct a public offering of ordinary shares, with the proceeds primarily allocated toward the clinical development of its product candidates and general corporate purposes. The company is focused on addressing the unmet needs in the multi-billion-dollar dry eye disease market with its drug candidate OK-101, which utilizes innovative MAP technology. The offering is contingent on market conditions and involves the potential for an additional 15% in shares to address over-allotments. It's essential for potential investors to review the preliminary prospectus for complete details on the offering.
Read more →OKYO▲ +23.3%on this news· ran to +44% by day 1shared move
OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer LONDON and
OKYO Pharma Limited has announced the appointment of William A. Clementi as Chief Operating Officer, effective September 1, 2023. With extensive experience in the pharmaceutical industry and a strong background in drug development, Clementi is expected to play a pivotal role in advancing OKYO's product portfolio, particularly for its treatment of dry eye disease. CEO Gary Jacobs expressed confidence that Clementi's leadership will drive growth and enhance the company's market position as it approaches key developmental milestones.
Read more →OKYO▼ -16.6%on this news
OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease Trial designed with a two-week run-in period to reduce the well-known placebo effect in trials
OKYO Pharma has announced that the randomized segment of its Phase 2 clinical trial for OK-101, aimed at treating dry eye disease, is now in progress. The trial features a two-week run-in period designed to reduce placebo effects. Approximately 240 subjects will be enrolled, randomly divided into three cohorts receiving either placebo or different concentrations of OK-101. Top-line data from the trial is anticipated in the fourth quarter of 2023, which could enhance insights into the drug's efficacy.
Read more →OKYOMay 2023 OKYO Pharma Limited (" OKYO " or " Company ") London Stock Exchange Delisting Further to the Dealing Announcement published by the FCA this morning, the board of directors of OKYO Pharma Limited (LSE: OKYO; NASD
OKYO Pharma Limited has confirmed the delisting of its ordinary shares from the London Stock Exchange, following an announcement by the FCA. The cancellation affects its shares on the LSE, though holders of American Depositary Shares (ADSs) on NASDAQ will not be impacted and will receive new ordinary shares through DTC. A share consolidation resulting in a 65 into 1 factor will take place, affecting the trading mechanism for existing shareholders. This transition involves significant changes for holders of both certificated and CREST shares.
Read more →OKYO▼ -8.9%on this newsshared move
OKYO PHARMA LIMITED ADS Program collapse - Commencement of trading of new ordinary shares on The Nasdaq Capital Market LONDON and
OKYO Pharma Limited has announced the commencement of trading for new ordinary shares on The Nasdaq Capital Market starting May 22, 2023. This follows the company's decision to collapse its American Depositary Share (ADS) program and a 65 into 1 reverse split of its ordinary shares. Shareholders approved this consolidation to align with the existing ADS ratio. The new ordinary shares will directly correlate to the previous share structure.
Read more →OKYO▲ +5.9%on this news
Exihibit 99.1 OKYO Pharma Limited (" OKYO " or " Company ") Change of Record Time and Last Day of Dealings London
OKYO Pharma Limited announced a change in the timetable regarding the delisting of its ordinary shares from the main market of the London Stock Exchange. The new delisting date is set for May 22, 2023, with last dealings on May 19, 2023. This change allows for late transfers into CREST and includes other adjustments related to share capital and new share listings on Nasdaq. While the company aims to address a significant need in dry eye disease treatment, the delisting might create uncertainties for current shareholders.
Read more →OKYO▼ -11.8%on this newsshared move
OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform Webull's community of active participants can now access OKYO's profile on the leading mobile-first brokerage platform London and New
OKYO Pharma Limited has announced its participation in the Webull Corporate Communications platform, which will facilitate better communication with shareholders. This platform allows for instant notifications regarding company news and presentations, effectively reaching a community of active investors. The company's founder emphasized the benefits of this mobile-first approach in enhancing stakeholder engagement and sharing vital corporate information.
Read more →OKYO▼ -11.8%on this newsshared move
May 2023 OKYO Pharma Limited (" OKYO " or " Company ") Change of Delisting Date to 22 May 2023 The board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), announces that it has delayed the date on which the
OKYO Pharma Limited has postponed the delisting of its ordinary shares from the LSE until May 22, 2023. This decision allows for a smoother transition for shareholders in moving their shares into the CREST system. However, once the delisting takes effect, ordinary shares will no longer be available for trading on the LSE's Main Market. The delisting will not impact the American Depositary Shares traded on Nasdaq.
Read more →OKYO▲ +6.5%on this news· ran to +37% by day 3
OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023
OKYO Pharma announced that it will present two papers on its drug candidate OK-101 at the American Society of Cataract and Refractive Surgery (ASCRS) 2023 in San Diego from May 5-8. The presentations, given by Dr. Pedram Hamrah, will discuss clinical findings related to OK-101's effects on treating dry eye disease and neuropathic corneal pain. This showcases OKYO's commitment to addressing significant unmet needs in the ophthalmology market and highlights the potential of OK-101 as a novel treatment option.
Read more →OKYO▲ +6.5%on this news· ran to +37% by day 3
May 2023 OKYO Pharma Limited (" OKYO " or " Company ") Result of General Meeting The board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is devel
OKYO Pharma Limited held a General Meeting where all resolutions were passed successfully by a significant majority. Key resolutions included share consolidation and share allotment to directors. The company aims to tackle the unmet needs in the dry eye disease market with its developing product, OK-101. This unanimous approval suggests strong backing from shareholders, reflecting confidence in the company's strategic direction.
Read more →OKYO▲ +6.5%on this news· ran to +37% by day 3
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) (UK MAR)
OKYO Pharma Limited announced two presentations on its investigational drug OK-101 at the upcoming American Society of Cataract and Refractive Surgery (ASCRS 2023) taking place from May 5-8, 2023. The presentations will discuss pre-clinical and animal model data showcasing the potential of OK-101 in treating dry eye disease and associated neuropathic pain. With its innovative approach, OK-101 aims to address significant unmet needs in the multi-billion-dollar dry eye market, highlighting the company's focus on advancing therapeutic options in ophthalmology.
Read more →OKYO▲ +9.9%on this news· ran to +22% by day 3shared move
OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease Trial designed with pre-specified primary efficacy endpoints discussed previousl
OKYO Pharma has announced the commencement of Phase 2 trials for OK-101, an ophthalmic treatment aimed at dry eye disease. This double-blinded, placebo-controlled study will enroll approximately 240 patients and includes major efficacy endpoints agreed upon with the FDA. Results from the trial are anticipated by the end of 2023, and positive outcomes could potentially shorten the timeline for FDA approval. OK-101 has demonstrated significant therapeutic potential in pre-clinical models, indicating a promising future for its clinical application.
Read more →OKYO▼ -6.6%on this news
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
OKYO Pharma has activated its first clinical trial site in the U.S. for a Phase 2 trial of OK-101, targeting dry eye disease. This multi-center, randomized, double-blinded trial aims to evaluate the safety and efficacy of OK-101, with patient enrollment expected to begin shortly. The compound is a novel therapeutic designed to reduce inflammation associated with dry eye disease and has shown promising results in preclinical studies. The CEO expressed optimism about progressing to patient visits within the next two weeks.
Read more →OKYONOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, OR INTO OR FROM ANY JURISDICTION IN WHICH THE SAME WOULD BE A VIOLATION OF THE LAWS OF SUCH JURISDICTION. NEITHER THIS ANNOUNC
OKYO Pharma Limited is moving forward with plans to cancel its ordinary shares from listing on the standard segment of the Official List of the Financial Conduct Authority. The company is developing OK-101, a promising treatment for dry eye disease that has shown anti-inflammatory benefits in preclinical models. A circular detailing these changes has been sent to shareholders ahead of a general meeting set for May 3rd, 2023, where further proposals will be discussed, including share consolidation.
Read more →OKYO▼ -12.3%on this newsshared move
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR
OKYO Pharma Limited has announced its intention to delist its ordinary shares from the London Stock Exchange due to negligible trading volume that does not justify the associated costs. The delisting is set to take effect on May 12, 2023. Following the delisting, the company will consolidate shares and aim to directly list its new ordinary shares on Nasdaq. This move will simplify operations for existing shareholders, but may impact the company’s visibility in the UK market.
Read more →OKYO▲ +10.3%on this news· ran to +24% by day 1shared move
Director Acquires Shares London and New York, NY, 30 March, 2023 - OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 t
OKYO Pharma Limited, an ophthalmology-focused biotech company, announced the purchase of 11,000 American Depositary Shares (ADSs) by Executive Chairman Gabriele Cerrone, which may reflect positive sentiment towards the company's potential. The shares were purchased at $1.41 each, indicating a commitment to the company's success. OKYO is developing OK-101, a treatment for dry eye disease, utilizing innovative technology to enhance its efficacy in the ocular environment. The decision to acquire shares may signal confidence in the upcoming market prospects for OK-101.
Read more →OKYO▲ +10.3%on this news· ran to +24% by day 1shared move
OKYO Pharma Today Announces Director Acquires Shares
OKYO Pharma Limited has announced that its Executive Chairman, Gabriele Cerrone, has acquired 11,000 shares of the company's American Depositary Shares (ADS) at $1.41 each, demonstrating confidence in the company's potential. OKYO is focused on addressing dry eye disease with its lead candidate, OK-101, which is developed to provide a long-acting treatment option. The acquisition takes place amid the company's ongoing efforts to advance its pipeline in the ophthalmology space.
Read more →OKYODirector acquires shares London and New York, NY, 29 March, 2023 - OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 t
OKYO Pharma Limited has announced that Gabriele Cerrone, its Executive Chairman, acquired 12,500 American Depositary Shares (ADSs) at $1.32 each, reflecting confidence in the company's prospects. OKYO is focused on developing OK-101, a treatment for dry eye disease, leveraging a novel drug candidate that demonstrates anti-inflammatory properties. The acquisition of shares signifies potential growth as the company addresses a significant market need in the ophthalmology sector.
Read more →OKYO▼ -6.1%on this newsshared move
PDMR Dealing London and New York, NY, 24 March, 2023 - OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry
OKYO Pharma Limited has announced a purchase of 10,000 American Depositary Shares (ADSs) by Gabriele Cerrone, the Executive Chairman, at a price of $1.40 per ADS. This transaction occurred on March 23, 2023, as part of the company's ongoing development of its drug candidate OK-101 for treating dry eye disease. OK-101 is designed to provide long-term effects and has shown promising results in animal models for its anti-inflammatory and pain-relieving properties. The investment reflects confidence in the company's focus on addressing an important area within ophthalmology.
Read more →OKYO▼ -6.1%on this newsshared move
OKYO Pharma Announces PDMR Dealing
OKYO Pharma Limited announced that Gabriele Cerrone, the Executive Chairman, purchased 10,000 American Depositary Shares (ADSs) at $1.40 each, demonstrating his commitment to the company's growth. The company is developing its lead product, OK-101, aimed at treating dry eye disease, a condition with significant market potential. OK-101 is designed to provide anti-inflammatory and pain relief benefits, emphasizing the innovative approach of using membrane-anchored peptide technology for enhanced effectiveness. This insider transaction may indicate investor confidence in the ongoing development of their therapeutic pipeline.
Read more →OKYO▲ +13.7%on this news
OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website. London and New York, NY
OKYO Pharma Limited has announced that its Phase 2 trial for the drug OK-101, aimed at treating dry eye disease, is now publicly listed on ClinicalTrials.gov. The company is in the process of activating clinical trial sites and preparing the drug for shipment. The first patient visit for the trial is anticipated to occur in early Q2 2023, with plans to release top-line data by Q4 2023. CEO Gary S. Jacob conveyed optimism regarding the potential of OK-101 to meet the needs of patients inadequately served by existing treatments.
Read more →OKYOTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIIONS (SI 2019/310) ("UK MA
OKYO Pharma Limited announced the awarding of stock options to its board of directors, reflecting strategic decisions in leadership compensation. The options, which total millions for top executives, will vest over four years and indicate the company's confidence in its ongoing drug development for dry eye disease. The lead product, OK-101, is aimed at treating this condition and has demonstrated effectiveness in preclinical models. This move comes as OKYO continues to seek advancements in an unmet multi-billion-dollar market.
Read more →OKYO▼ -15.6%on this news· ran to -27% by day 3shared move
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION IN WHI
OKYO Pharma Limited has announced a Global Private Placement raising approximately $5.74 million to fund the initial Phase 2 clinical trial of OK-101 for treating dry eye disease. This offering includes new American Depositary Shares and ordinary shares at a set price, with key management and directors participating as a show of confidence. The offering is expected to be completed on March 14, 2023, subject to standard closing conditions. The company intends to use the net proceeds for working capital and advancing its clinical trial.
Read more →OKYO▼ -15.6%on this news· ran to -27% by day 3shared move
OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management
OKYO Pharma Limited has announced a global private placement raising approximately U.S.$5.74 million to fund the Phase 2 clinical trial of its treatment OK-101 for dry eye disease. The offering includes the issuance of new American Depositary Shares and ordinary shares, with participation from directors and senior management who are converting deferred salaries into shares. The offering aims to utilize the net proceeds for working capital and advancing clinical development. The closing of the U.S. offering is anticipated to occur soon, subject to customary conditions.
Read more →OKYO▼ -9.4%on this news· ran to -24% by day 1shared move
OKYO Pharma Limited Prices $5.3 Million Offering of ADSs London
OKYO Pharma Limited has priced a public offering of 3,503,665 American Depositary Shares (ADSs) at $1.50 each, expecting to raise around $5.3 million. The proceeds from the offering will support the initial Phase 2 clinical trial of the company's drug OK-101 aimed at treating patients with dry eye disease (DED). Additionally, a concurrent offering in the UK raised $0.3 million through ordinary shares, indicating strong management support. The offering is expected to close on March 15, 2023, subject to standard conditions.
Read more →OKYO▼ -7.1%on this news
OKYO Pharma Limited (" OKYO ", " OKYO Pharma " or the " Company ") OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease London and New York,
OKYO Pharma has announced that its GMP packaged OK-101 drug has successfully cleared customs in the U.S., preparing for a Phase 2 clinical trial for dry eye disease (DED). The company is working on generating randomization codes and authorizing clinical sites, with the first patient visit anticipated in Q1 2023 and top-line data expected to be released in Q4 2023. CEO Gary S. Jacob expressed optimism about the trial, emphasizing the drug's potential to introduce new treatment options for DED patients who currently have limited therapies available.
Read more →OKYO▼ -7.1%on this news
OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease
OKYO Pharma Limited announced that its GMP packaged drug, OK-101, has cleared customs in the United States, enabling the initiation of its Phase 2 clinical trial for dry eye disease (DED). The trial aims to address the unmet needs within a significant market for DED patients. The company's CEO expressed excitement about progressing toward clinical trials, asserting that OK-101 could provide innovative therapeutic options. The first patient visit is anticipated in Q1 2023, with top-line data expected in Q4 2023.
Read more →OKYO▼ -21.3%on this newsshared move
OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to its Scientific Advisory Board World-renowned Ophthalmologist with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Joins Advisory Board
OKYO Pharma has appointed Dr. Jay S. Pepose to its Scientific Advisory Board, bringing significant expertise in ocular surface diseases. Dr. Pepose will guide clinical programs for the company’s lead product, OK-101, aimed at treating dry eye disease. The company plans to begin enrollment for Phase 2 clinical trials of OK-101 in early 2023. This appointment is anticipated to enhance the company's profile and the understanding of the product's potential in the clinical community.
Read more →OKYO▼ -17.4%on this news· ran to -44% by day 3shared move
OKYO Pharma Limited (" OKYO ", " OKYO Pharma " or the " Company ") OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on February 21-23, 2023. London and New York, NY
OKYO Pharma Limited has announced its participation in the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston. CEO Gary S. Jacob will present on the development of OK-101, a drug aimed at treating dry eye disease, which recently received FDA IND clearance. This presentation is set to highlight findings from preclinical studies as well as upcoming clinical trial plans. The company is focused on addressing significant unmet needs in the dry eye market with its innovative therapy.
Read more →OKYO▼ -17.4%on this news· ran to -44% by day 3shared move
OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on February 21-23, 2023.
OKYO Pharma Limited announced that its CEO, Dr. Gary S. Jacob, will present at the 2nd Annual GPCRs-Targeted Drug Discovery Summit in Boston from February 21-23, 2023. His presentation will cover the development of OK-101, a candidate for treating dry eye disease, including the firm's recent FDA clearance for its Investigational New Drug application. Dr. Jacob's talk follows an introductory presentation by Dr. Alan Kopin, who will discuss the research and testing behind OK-101. The company plans to initiate a Phase 2 trial for OK-101 in early 2023.
Read more →OKYOFebruary 2023 OKYO PHARMA LIMITED ("OKYO" or "the Company") Allotment of Ordinary Shares and Total Voting Rights OKYO Pharma Limited (LSE:OKYO; NASDAQ: OKYO) (the " Company ") today announces that pursuant to an agreemen
OKYO Pharma Limited has announced the allotment of 2,177,500 ordinary shares as part of an agreement with TraDigital Marketing for consulting services. Applications are being made for these shares to be listed on the FCA's Official List and traded on the London Stock Exchange, with a targeted admission date of February 16, 2023. Following this allotment, the total issued share capital of the company will amount to approximately 1.42 billion ordinary shares with voting rights. This move aims to support the company in its ongoing efforts to address dry eye diseases and chronic pain.
Read more →OKYOOKYO PHARMA LIMITED ("OKYO" or "the Company") Interim Results - availability The OKYO Pharma Interim Report for the half-year ended 30 September 2022 (the "Interim Report") is available on the Company's website and can b
OKYO Pharma Limited has made its Interim Report for the half-year ending September 30, 2022 available on its website and through the National Storage Mechanism. The report includes details regarding the company’s interim results, providing investors with transparency about its financial performance. Stakeholders can access the document online for further insights into the company's operations during this period.
Read more →OKYO▼ -13.2%on this newsshared move
Okyo Pharma Limited Interim Results for the Six Months Ending 30 September 2022 London and New York, NY
Results for the Six Months Ending 30 September 2022 and New York, NY, December 30, 2022 OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DED) to address the significant unmet need in
Read more →OKYOOKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease
-OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease- -Phase 2 study expected to open to enrollment in the first quarter 2023- LONDON and NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) --
Read more →OKYOOKYO Pharma Limited ("OKYO" or the "Company") OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease - OK-101 first-in-human Phase 2 trial will incorporate primary and
Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease- 2 study expected to open to enroll
Read more →OKYOOKYO Pharma Limited ("OKYO" or the "Company") OKYO to Participate at Biotech Showcase London and New York, NY., 21 December, 2022 - OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutic
to Participate at Biotech Showcase and New York, NY., 21 December, 2022 - OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-bi
Read more →OKYO▼ -10.3%on this news
OKYO Pharma Limited (" OKYO " or the " Company ") OKYO publicly files a registration statement with the SEC London and New York, N.Y., 6 December 2022 - OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-foc
("OKYO" or the "Company") publicly files a registration statement with the SEC and New York, N.Y., 6 December 2022 - OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to addres
Read more →OKYOOKYO Pharma Limited - Change of Auditor
LONDON and NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar dry eye
Read more →OKYOOKYO Pharma Limited ("OKYO" or the "Company") Grant of options -PDMR dealing London and Boston, M.A., 24 November, 2022 - OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company
of options -PDMR dealing and Boston, M.A., 24 November, 2022 - OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dolla
Read more →OKYOOKYO Pharma Limited – PDMR dealing
LONDON and BOSTON, Nov. 24, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar market, an
Read more →OKYOOKYO Pharma Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease
-OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease- LONDON and BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-p
Read more →OKYOOKYO Pharma Limited ("OKYO" or the "Company") OKYO Pharma Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease - OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy end
Pharma Announces U.S. IND Filing on OK-101 for the first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease- and Boston, MA, November 21, 2022 - OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an
Read more →OKYO▼ -11.8%on this news
OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease Monday, November 14 th @ 8 am ET, registration details below
Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease November 14th @ 8 am ET, registration details below YORK, November 10, 2022 - OKYO Pharma Ltd (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), an ophthalmology bio-pharm
Read more →OKYOOKYO Pharma Ltd. Announces Participation in The ThinkEquity Conference New York, New York
Pharma Ltd. Announces Participation in The ThinkEquity Conference York, New York- October 20, 2022 - OKYO Pharma Ltd. (NASDAQ:OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in
Read more →OKYOOKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report New York and London
Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report York and London- September 8, 2022 - OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO;), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye d
Read more →OKYO▲ +5.8%on this newsshared move
September 2022 OKYO Pharma Limited (" OKYO " or " Company ") Result of Annual General Meeting The board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an
of Annual General Meeting board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative approach to dry eye care and ocular pain, is pleased to announce that at the Annual General Meeting ("AGM") of the Co
Read more →OKYO▲ +5.8%on this newsshared move
OKYO Pharma Limited: Result of Annual General Meeting
LONDON and NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- The board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative approach to dry eye care and ocular pain, is pleased to announce that at the Annual Ge
Read more →OKYO▲ +22.4%on this news· ran to +41% by day 3
OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm OK-101 to treat ocular diseases, including Dry Eye Disease (D
Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing OK-101 to treat ocular diseases, including Dry Eye Disease (DED), uveitis, allergic conjunctivitis, and ocular pain. Successful pre-IND meeti
Read more →OKYO▼ -10.8%on this news
August 2022 OKYO Pharma Limited ("OKYO" or the "Company") Notice of Annual General Meeting OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative approach to dry e
of Annual General Meeting Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative approach to dry eye care and ocular pain, is pleased to announce that it will hold its annual general meeting ("AGM") on 7 September 2022 at 12.0
Read more →OKYOOKYO Pharma Limited Final audited results for the year ended 31 March 2022 LONDON and
audited results for the year ended 31 March 2022 and NEW YORK, August 16, 2022. OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO) (the "Company") is pleased to announce its final audited results for the year ended 31 March 2022. of OKYO-101 studies during the last year OK-101 i
Read more →OKYOPDMR Dealing London and New York, 9 June, 2022 - OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative approach to dry eye care and ocular pain, today announces t
and New York, 9 June, 2022 - OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative approach to dry eye care and ocular pain, today announces that it has been notified that Willy Simon, a non-executive director, purchased
Read more →OKYOOKYO Pharma Limited - PDMR Dealing
LONDON and NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative approach to dry eye care and ocular pain, today announces that it has been notified that Willy Simon, a non-execu
Read more →OKYO▼ -9.9%on this news· ran to -34% by day 3
PDMR Dealing London and Boston, MA, 20 May, 2022 - OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a life sciences company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases
and Boston, MA, 20 May, 2022 - OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a life sciences company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announces that it has been notified that Panetta Partn
Read more →OKYO▲ +9.5%on this news· ran to -27% by day 3shared move
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSE OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF UNITED KINGDOM ("UK") DOMESTIC LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS ( SI
ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSE OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF UNITED KINGDOM ("UK") DOMESTIC LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT
Read more →OKYO▲ +9.5%on this news· ran to -27% by day 3shared move
OKYO Pharma Limited Announces Closing of Public Offering and Nasdaq Listing
LONDON, May 19, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a life sciences company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announced the
Read more →OKYO▼ -16%on this news· ran to -27% by day 3shared move
PDMR Dealing London and New York, NY, 18 May, 2022 - OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseas
and New York, NY, 18 May, 2022 - OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announces that it has been notified that Panetta Par
Read more →OKYOOKYO Pharma Limited Announces Pricing of Initial Public Offering of ADSs in the U.S. with director participation
LONDON, May 17, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), a life sciences company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases (“DED”) and ocular pain, is pleased to anno
Read more →OKYOOKYO Pharma Limited Announces Pricing of Public Offering and Nasdaq Listing
LONDON, May 16, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, announced the prici
Read more →OKYOOKYO Pharma ("OKYO" or the "Company") - Announces Two Presentations at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
OK-101 ameliorates neuropathic corneal pain in a mouse model of ciliary nerve ligation BAM8-22 peptide analog OK-201 alleviates neuropathic corneal pain in mice LONDON, April 27, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company foc
Read more →OKYOOKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SEC for a proposed dual-listing on the Nasdaq Capital Market and Offering in the United States
LONDON, March 07, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF) ("OKYO" or the "Company"), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, is pleased to announce t
Read more →OKYOOKYO Pharma ("OKYO" or the "Company") - announces issuance of U.S. Patent No. 11,254,720 covering OKYO’s dry eye drug candidate OK-101 for use to treat ocular neuropathic pain
LONDON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announced that the patent entitled “Methods a
Read more →OKYOOKYO Pharma Limited ("OKYO" or the "Company") - Conversion of CLNs, cashless exercise of Warrants, and issue of equity
LONDON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, is pleased to announce that it has today issued 403
Read more →OKYOOKYO Pharma Limited ("OKYO" or the "Company") - OKYO Pharma announces Successful Completion of a Pre-IND Meeting with the FDA on the Development of OK-101 to Treat Dry Eye Disease
LONDON and BOSTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announced the successful completio
Read more →OKYOOKYO Pharma Limited ("OKYO" or the "Company") - Grant of options – Director and PDMR dealings
LONDON, Feb. 01, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, announces that the board of directors of the Compan
Read more →OKYOOKYO Pharma Limited- PDMR Dealing
LONDON and BOSTON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announces that it has been notifie
Read more →OKYOOKYO Pharma Limited - Interim results for the six months to 30 September 2021
LONDON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO) a biopharmaceutical company developing next-generation therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain today announces its interim results for the six months en
Read more →OKYOOKYO Pharma announces issuance of U.S. Patent No. 11,197,906 covering OKYO Pharma’s drug candidate OK-101 for use to treat dry eye disease
LONDON and BOSTON, Dec. 14, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announced that the patent entitled
Read more →OKYOOKYO Pharma Limited ("OKYO" or the "Company") Announces First-in-Class Drug Candidate OK-101 Displaying Both Anti-inflammatory and Ocular Pain-Reducing Potential to Treat Dry Eye Disease
LONDON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases (DED) and ocular pain, is pleased to announce that its drug candidat
Read more →OKYOOKYO Pharma Limited ("OKYO" or the "Company") to File IND in Q3 2022 for OK-101 to treat Dry Eye Disease ("DED") and to go directly to a Phase 2 Human Clinical Efficacy Trial in DED Patients with a planned start date in Q4 2022 on an accelerated basis
LONDON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), the biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, is pleased to announce that working with Ora, Inc
Read more →OKYOOKYO Pharma Limited: Directorate Change
LONDON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ("OKYO" or the "Company") today announces that Bernard Denoyer has been appointed as a non-executive director of the Company with immediate effect. Bernard F. Denoyer (age: 74) Bernard F. Denoyer has 49 years of fina
Read more →OKYOOKYO Pharma Limited ("OKYO" or the "Company") - Result of Annual General Meeting
LONDON, Sept. 27, 2021 (GLOBE NEWSWIRE) -- OKYO (LSE: OKYO), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that at the Annual General Meeting,
Read more →OKYOOKYO Pharma Limited ("OKYO" or the "Company") - Notice of Annual General Meeting
LONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that it will hold it
Read more →OKYOOKYO Pharma Limited Announces final audited results for the year ended 31 March 2021
LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (the “Company”) is pleased to announce its final audited results for the year ended 31 March 2021. Summary of OKYO-101 studies during the last year OK-101 is designed to target a chemokine-like receptor 1, or CMKLR1,
Read more →OKYO("OKYO" or the "Company") - OKYO Pharma Retains Ora Inc. to Perform Regulatory Development of OK-101 for Dry Eye Indications
LONDON and BOSTON, June 29, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, is pleased to announce that it has retai
Read more →OKYO("OKYO" or the "Company") - OKYO Pharma Announces Positive Data and Results in an Animal Model using Topically Administered OK-201 to Treat Neuropathic Ocular Pain
LONDON and BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, is pleased to announce positive results
Read more →OKYOOKYO Pharma Limited ("OKYO" or the "Company") - OKYO announces appointment of Dr Rajkumar Patil as Chief Scientific Officer
LONDON, March 29, 2021 (GLOBE NEWSWIRE) -- OKYO (LSE: OKYO; OTCQB: EMMLF), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, announces that it has appointed Dr Rajkumar P
Read more →OKYOOKYO Pharma Limited ("OKYO" or the "Company") - Issue of Equity
LONDON, March 01, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ("OKYO" or the "Company") today announces that it has issued 250,000 ordinary shares of no par value ("Ordinary Shares"), credited as fully paid, at a price of 4.5p per share on the exercise of 250,000 options. Appli
Read more →OKYOOKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated Peptide Analogues for treating Ocular Pain and Inflammation
LONDON, Feb. 23, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ("OKYO" or the "Company"), a biotechnology company focused on the development of novel drugs to treat inflammatory eye diseases and chronic ocular pain, today announced that patent No. 10,899,796 entitled “Compounds an
Read more →OKYOOKYO Pharma Limited ("OKYO" or the "Company") - OKYO announces filing of a patent application covering the use of Chemerin and associated analogues to treat “cytokine storm” associated with COVID-19 and ARDS
LONDON and BOSTON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- OKYO (LSE: OKYO; OTCQB: EMMLF), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, announces that it has today submit
Read more →OKYOOKYO Pharma Limited ("OKYO" or the "Company") - Result of the Annual General Meeting
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF S
Read more →OKYOOKYO Pharma Limited ("OKYO" or the "Company") - Appointment of Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board
LONDON, Aug. 19, 2020 (GLOBE NEWSWIRE) -- OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that that Dr. Napoleone Ferrara, MD, Professor
Read more →OKYOOKYO Pharma Limited ("OKYO" or the "Company") - Issue of additional convertible loan notes to raise 1,437,104 and intention to seek dual listing on NASDAQ
LONDON, Aug. 18, 2020 (GLOBE NEWSWIRE) -- OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that it has raised an additional £1,437,104 thr
Read more →OKYOOKYO Pharma Limited ("OKYO" or the "Company") - Company Presentation
LONDON, Aug. 03, 2020 (GLOBE NEWSWIRE) -- OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that, further to the announcement made on Frida
Read more →OKYOOKYO Pharma Limited - Upcoming Presentation
LONDON, July 31, 2020 (GLOBE NEWSWIRE) -- OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that Kunwar Shailubhai, Ph.D., the Company’s CE
Read more →OKYOOKYO Pharma Limited ("OKYO" or the "Company") - Issue of convertible loan notes to raise 3,500,000
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF S
Read more →Competitive Position
How OKYO ranks across every disease it competes inCompetitive Position is a premium feature
See how OKYO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial